Title
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
Date Issued
01 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Weisberg S.P.
Connors T.J.
Zhu Y.
Lin W.H.
Wontakal S.
Szabo P.A.
Wells S.B.
Dogra P.
Gray J.
Idzikowski E.
Stelitano D.
Bovier F.T.
Davis-Porada J.
Matsumoto R.
Poon M.M.L.
Chait M.
Mathieu C.
Horvat B.
Decimo D.
Hudson K.E.
Zotti F.D.
Bitan Z.C.
La Carpia F.
Ferrara S.A.
Mace E.
Milner J.
Moscona A.
Hod E.
Porotto M.
Farber D.L.
Columbia University
Publisher(s)
Nature Research
Abstract
Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are associated with age1,2. Adults develop respiratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe form, while children are largely spared from respiratory illness but can develop a life-threatening multisystem inflammatory syndrome (MIS-C)3–5. Here, we show distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating IgG antibodies specific for the S protein but not the N protein. Moreover, children with and without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children independent of whether they develop MIS-C, with implications for developing age-targeted strategies for testing and protecting the population.
Start page
25
End page
31
Volume
22
Issue
1
Language
English
OCDE Knowledge area
Sistema respiratorio Inmunología Enfermedades infecciosas
Scopus EID
2-s2.0-85095604596
PubMed ID
Source
Nature Immunology
ISSN of the container
15292908
Sponsor(s)
We thank F. Cosset for the donation of the Vero E6 cells. We thank the Medical ICU nurse champions, C. Garcellano, T. Drukdak, H. Avila Raymundo, L. Wagner and R. Lee, who all led the efforts to obtain patient samples for the adult ARDS patients; E. Hernandez and L. Gomez for their roles as clinical coordinators; and the nurses and clinical staff in the Pediatric Intensive Care Unit of MSCHONY. We acknowledge the dedication, commitment and sacrifice of the other nurses, providers and personnel who helped care for these patients during the COVID-19 crisis. We acknowledge the suffering and loss of our COVID-19 patients and that of their families and our community. We also acknowledge the staff of the Columbia University Biobank for their efforts in collecting and preserving COVID-19 patient samples for research studies. This work was supported by National Institutes of Health (NIH) grant nos. AI128949, AI100119 and AI106697 awarded to D.L.F.; NIH grant nos. AI121349, NS091263, NS105699 and AI146980 awarded to M.P.; Fondation de France and ANR Flash-Covid-19, ANR-20-COVI-000 awarded to B.H. and M.P.; and grant no. AI114736 awarded to A.M. S.W. is supported by NIH grant no. K08DK122130. T.J.C. is supported by NIH grant no. K23 AI141686. The funders/sponsors had no role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; the preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication.
Sources of information: Directorio de Producción Científica Scopus